

Bioproducts Manufacturing Facility

Presentation to the bioproducts industry 22 April 2021





Addressing a very real need

- New Zealand is a world leader in developing novel biologically based technologies (biorationals, bioproducts) to sustainably manage plant and animal prodution.
- A bottleneck to commecialisation of microbe-based technologies is a large scale production facility, dedicated to producing microbes at scale and economically for agriculture, forestry and environmental remediation.
- One stop shop formulation, fermentation, QA/GMP & verification, packaging



M	issi	ion

To commision and operate a production facility here in New Zealand for the development and manufacturing of bioproducts, from biopesticides to biofertilizers and beyond.

Vision


To become a world-class centre of excellence in bioproducts development, testing and manufacture, allowing local companies a low-risk and low-cost path to market of new and existing products onshore in New Zealand.

Values

- Collaboration and knowledge sharing
- Commitment to GMP throughout R&D and production
- Innovation
- Cultivate strong science partnerships to guarantee commercial success
- Commitment to working with government, agencies and private sector



Building a value chain for bioproducts R&D and production in New Zealand



Solving the one thing that's missing – a production facility in New Zealand




The Facility

- Full product development capabilities, from lab scale through to scaled production, capable of formulating a range of microbial-based products for New Zealand and international companies.
- Located on site at Lincoln University.
- Fermenters from 1 litre to 5,000 litres
- Laboratory and production facility suitable for a wide variety of bioproducts
- Equipment includes a range of fermenters from small test size to commercial scale, extruders, centrifuge, freeze dryer
- Test batch to commercial scale production



BioSouth Facility – Preliminary Design





A commitment to GMP



- BioSouth's facility will have full quality and regulatory compliance around GMP
- CFR's 9 &21
- Full pharmacopeial requirements for multiple markets:
 - USP
 - EU
 - Japan



Project team



Travis Glare

Director of the Bio-Protection Research Centre at Lincoln University. Professor of Applied Entomology at Lincoln and extensive experience at AgResearch in the field of biopesticides.

- Vast experience in biopesticide R&D
- Strong knowledge around plant design and operation
- Extensive networks with key stakeholders



Randal Fitzgerald

Randal has over thirty years of experience in developing technologies for the diagnostic, medical device, pharmaceutical, biopharmaceutical, and agriculture products. Ex-COO of Proliant Biologicals and has led teams for Fortune 500 companies.

- Track record in plant build and commissioning
- Strong science background
- GMP and quality system establishment and audit



Project team



• William Wattie

Currently Managing Director of Astrea Proteins and Fats S.A. in Brazil, an advanced pet food ingredients manufacturer, but with a background in trade development in government and the private sector.

- Greenfield site development and project management
- Multi-party negotiations and agreements
- International business partnerships



John Mead

John has over twenty years of practical experience in delivering on challenging processing plant builds and start-ups in Australasia and around the world.

With experience in food and pharmaceuticalgrade plant design, fabrication, build and start-up, he is ideally qualified to lead the greenfield build.

- Track record in pharma-grade plant build
- Agency agreements with key suppliers
- Project management

Project team






Simon Egan

Simon was previously CEO of Greenlea Meats and a founder of BioArra in the United States, a manufacturer of high-value blood serum products for the scientific and pharmaceutical markets.

- Leadership of high-performance teams
- Product development
- Business growth and development



Potential project timeline



and BioSouth



Engagement with stakeholders

- Go-no go decision based on expressions of interest from the biopesticides companies
- Two-way NDA and information sharing agreement between BioSouth and potential customers
- No confidential information shared with third parties unless consented
- Discussions with other stakeholders in parallel, including industry bodies, government departments, CRIs, potential offshore partners
- Transparent process and open dialogue
- Preferential pricing and access packages planned for foundation customers
- Business case complete and go/no go decision by 30 June 2021





Thank you



Simon Egan e. <u>segan03@gmail.com</u> m. 029 957 3543

John Mead e. john.mead@liquiddynamics.co.nz m. 021 274 2268

Travis Glare <u>travis.glare@Lincoln.ac.nz</u> m. 027 283 0350